idiopath
pneumonia
syndrom
cryptogen
organ
pneumonia
hematopoiet
cell
transplant
idiopath
pneumonia
syndrom
ip
uncommon
deadli
complic
transplant
mani
clinic
phenotyp
better
understand
ip
pathobiolog
role
occult
infect
need
develop
effect
therapi
drug
given
condit
graftversushost
diseas
prevent
treatment
known
potenti
pulmonari
toxic
venou
thromboembol
pulmonari
hypertens
caus
pulmonari
symptom
normal
chest
imag
hematopoiet
cell
transplant
proteinosi
venou
thromboembol
pulmonari
hypertens
million
hematopoiet
cell
transplant
hct
perform
worldwid
treat
spectrum
benign
malign
diseas
surviv
rate
hct
increas
time
advanc
donor
recipi
select
pretranspl
condit
infect
graftversushost
diseas
gvhd
prevent
treatment
blood
transfus
manag
critic
care
nonrelaps
mortal
within
day
allogen
hct
decreas
compar
year
respect
one
highvolum
us
transplant
center
despit
improv
overal
surviv
noninfecti
lung
injuri
remain
import
caus
morbid
mortal
hct
recent
call
arm
urg
concert
effort
toward
identifi
effect
prevent
therapeut
strategi
articl
focus
noninfecti
pulmonari
complic
manifest
within
first
month
hct
first
section
review
epidemiolog
pathogenesi
treatment
outcom
diffus
lung
injuri
collect
refer
idiopath
pneumonia
syndrom
ip
clinic
relev
subtyp
includ
diffus
alveolar
hemorrhag
dah
cryptogen
organ
pneumonia
second
section
review
pulmonari
toxic
drug
commonli
use
condit
gvhd
prophylaxi
treatment
final
section
summar
limit
knowledg
less
common
pulmonari
syndrom
occur
hct
includ
pulmonari
alveolar
nation
institut
health
sponsor
workshop
goal
unifi
research
lung
complic
transplant
standard
ip
definit
propos
group
requir
evid
widespread
alveolar
injuri
absenc
activ
lower
respiratori
tract
infect
lrti
lrti
could
exclud
either
nonrespons
broadspectrum
antibiot
least
one
bronchoscopi
bronchoalveolar
lavag
bal
test
neg
extens
panel
known
pulmonari
pathogen
transbronchi
biopsi
recommend
clinic
permiss
mani
clinic
syndrom
includ
ip
definit
includ
acut
respiratori
distress
syndrom
ard
acut
interstiti
pneumon
delay
pulmonari
toxic
syndrom
periengraft
respiratori
distress
syndrom
dah
cryptogen
organ
pneumonia
bronchiol
obliteran
syndrom
work
group
acknowledg
clinic
heterogen
within
definit
recommend
multidisciplinari
investig
improv
understand
ip
pathobiolog
motiv
novel
treatment
emerg
new
diagnost
technolog
newli
recogn
pulmonari
pathogen
result
updat
origin
ip
definit
recent
publish
revis
requir
exclus
heart
failur
acut
kidney
injuri
iatrogen
fluid
overload
caus
widespread
alveolar
injuri
modifi
definit
box
incorpor
evolv
understand
pulmonari
pathogen
appreci
inflammatori
lung
injuri
hydrostat
pulmonari
edema
coexist
knowledg
ip
epidemiolog
contemporari
era
limit
age
current
avail
evid
heterogen
definit
use
tabl
two
larg
retrospect
cohort
studi
appli
standard
ip
definit
found
result
similar
earlier
studi
noninfecti
interstiti
pneumon
idiopath
interstiti
pneumon
incid
ip
popul
includ
children
adult
autolog
hct
allogen
hct
median
time
ip
onset
day
rang
day
risk
factor
includ
highgrad
gvhd
age
totalbodyirradi
tbi
dose
transplant
indic
mechan
ventil
use
ip
case
mortal
rate
approxim
hospit
within
day
discharg
recent
studi
ad
prior
hct
receipt
blood
compon
transfus
list
ip
risk
factor
although
ip
definit
studi
popul
condit
regimen
observ
time
vari
across
studi
consist
high
rate
respiratori
failur
death
report
outcom
better
children
adult
updat
studi
need
better
understand
potenti
target
intervent
inform
bedsid
convers
prognosi
histopatholog
ip
span
spectrum
includ
diffus
alveolar
damag
lymphocyt
bronchiol
organ
pneumonia
interstiti
pneumon
fig
effort
elucid
pathogenesi
ip
challeng
heterogen
syndrom
concurr
process
modifi
biolog
extrapulmonari
gvhd
use
mechan
ventil
current
knowledg
ip
pathobiolog
deriv
larg
studi
use
murin
model
recapitul
mani
biolog
featur
physiolog
chang
observ
clinic
set
experiment
ip
model
cytokinechemokinemedi
signal
transduct
cascad
orchestr
noninfecti
lung
inflamm
injuri
fig
tumor
necrosi
factor
tnf
interferon
ifn
g
lipopolysaccharid
lp
propos
mediat
key
pathway
converg
lung
earli
ip
develop
tnfa
releas
injur
tissu
may
enhanc
costimulatori
commun
donor
cell
migrat
lung
radioresist
host
monocytesantigenpres
cell
dysregul
interleukin
il
low
ifng
level
promot
expans
alloreact
donor
cell
includ
helper
h
cell
neutrophil
alveol
note
later
stage
experiment
ip
hypothes
lp
transloc
intestin
damag
condit
acut
gvhd
circul
lung
activ
neutrophil
macrophag
exact
mechan
propos
composit
biolog
ultim
injur
host
cell
fulli
elucid
end
sever
pulmonari
dysfunct
result
capillari
leak
pulmonari
edema
disrupt
pulmonari
surfact
injuri
case
apoptosi
bronchial
epithelium
alveolar
epithelium
vascular
endothelium
clinic
studi
examin
cytokin
level
patient
ip
support
experiment
find
blood
bal
fluid
level
tnfa
signal
lpsbind
protein
elev
ip
find
could
consist
complex
interact
donor
cell
recipi
macrophag
studi
support
hypothes
model
dual
role
play
tnfa
lp
ip
pathogenesi
suggest
overlap
biolog
occur
system
lung
compart
cytokin
monocyt
chemoattract
protein
mcp
also
elev
clinic
ip
although
studi
import
progress
toward
understand
ip
pathobiolog
remain
work
done
exampl
known
biolog
vari
ip
subtyp
recent
studi
seo
colleagu
highlight
anoth
import
limit
understand
ip
use
modern
molecular
diagnost
technolog
investig
detect
occult
potenti
pathogen
bal
fluid
sampl
taken
clinic
diagnos
ip
case
patient
occult
microorgan
experienc
wors
outcom
studi
suggest
infect
may
play
unrecogn
role
ip
develop
phenotyp
sever
altern
possibl
clinic
research
basic
understand
ip
aros
bias
misclassif
true
infecti
pneumonia
ip
addit
research
need
progress
abil
develop
new
prevent
therapeut
strategi
ip
effect
method
identifi
patient
highest
risk
ip
predict
respons
specif
immunomodulatori
therapi
could
focu
prevent
effort
treatment
like
benefit
use
unbias
proteom
approach
schlatzer
colleagu
compar
profil
peptid
found
blood
collect
day
hct
individu
subsequ
develop
ip
control
investig
gener
intern
valid
highperform
model
use
vari
combin
peptid
predict
develop
ip
respons
treatment
etanercept
solubl
tnfabind
protein
sever
protein
acut
phase
respons
signal
pathway
select
inclus
predict
model
chang
throughout
cours
ip
consist
dysregul
innat
immun
although
singl
studi
requir
valid
independ
popul
special
attent
potenti
role
occult
infect
highlight
biomark
may
use
advanc
understand
ip
sever
line
inquiri
examin
associ
genet
polymorph
biomark
develop
end
point
overlap
ip
acut
lung
injuri
gvhd
whether
result
studi
generaliz
ip
potenti
identifi
new
therapeut
target
unknown
highdos
system
corticosteroid
support
care
current
standard
treatment
ip
metcalf
colleagu
first
report
observ
treat
peopl
dah
follow
autolog
allogen
hct
surviv
hospit
discharg
higher
treat
mg
methylprednisolon
daili
day
follow
taper
surviv
vs
lower
dose
support
therapi
alon
treatment
group
experienc
similar
infect
rate
subsequ
cohort
studi
includ
ip
case
confirm
better
surviv
corticosteroid
show
similar
outcom
compar
mgkgd
prednisolon
mgkgd
observ
studi
corticosteroid
may
withheld
sickest
patient
subsequ
die
result
inflat
estim
benefit
regardless
surviv
unaccept
low
despit
treatment
effort
improv
outcom
seri
studi
motiv
preclin
data
examin
clinic
impact
modul
tnfa
ip
observ
studi
coadministr
methylprednisolon
mgkgd
etanercept
mgkg
given
twice
weekli
maximum
dose
result
low
toxic
improv
pulmonari
physiolog
increas
shortterm
surviv
ip
contrast
random
placebocontrol
trial
etanerceptglucocorticoid
combin
therapi
show
surviv
benefit
importantli
enrol
termin
earli
result
increas
chanc
falseneg
result
anoth
trial
children
receiv
etanercept
experienc
higher
rate
surviv
without
supplement
oxygen
day
enrol
compar
histor
control
although
longterm
surviv
studi
etanercepttr
children
remain
aliv
year
later
higher
surviv
rate
seen
prior
studi
corticosteroid
therapi
limit
trial
includ
lack
contemporari
control
group
potenti
particip
differ
characterist
broader
popul
risk
ip
whether
etanercept
improv
surviv
like
benefit
remain
unansw
agent
may
meaning
modifi
biolog
ip
howev
current
avail
evid
support
routin
use
keratinocyt
growth
factor
kgf
protect
chemoradiationinduc
epitheli
cell
injuri
enhanc
tissu
repair
limit
ip
sever
mice
gvhd
sever
clinic
set
limit
data
regard
potenti
impact
antioxid
ip
conflict
antifibrinolyt
therapi
may
improv
outcom
directli
reduc
hemorrhag
indirectli
reduc
number
blood
compon
transfus
though
result
small
observ
studi
mix
defibrotid
profibrinolyt
therapi
prevent
improv
surviv
sinusoid
obstruct
syndrom
complic
hct
also
aris
endotheli
injuri
use
ip
howev
may
limit
increas
risk
hemorrhag
macrolid
suppress
product
macrophagederiv
cytokin
implic
ip
pathogenesi
improv
cryptogen
organ
pneumonia
small
studi
outsid
hct
set
macrolid
may
similarli
benefit
patient
ip
administ
dose
higher
commonli
use
infect
prophylaxi
recent
discoveri
cell
import
role
ip
gvhd
may
lead
new
direct
use
halofuginon
therapi
ip
engraft
syndrom
es
defin
fever
rash
occur
within
day
neutrophil
engraft
risk
factor
es
includ
male
sex
myeloabl
condit
highdos
tbi
nonmatchedrel
stem
cell
donor
subset
patient
es
develop
noninfecti
pulmonari
infiltr
hypoxemia
characterist
periengraft
respiratori
distress
syndrom
perd
also
known
capillari
leak
syndrom
fig
capillari
leak
perd
result
activ
engraft
neutrophil
possibl
respons
condit
toxic
tcell
autoreact
perd
occur
autolog
hct
report
incid
vari
wide
allogen
hct
wherebi
neutrophil
activ
may
compon
acut
gvhd
origin
descript
perd
autolog
hct
patient
mechan
ventil
die
sever
perd
case
treat
system
corticosteroid
improv
wherea
es
associ
transplantrel
mortal
better
respons
corticosteroid
higher
surviv
perd
rel
ip
subtyp
highlight
fact
ip
subtyp
may
importantli
differ
biolog
dah
subtyp
ip
defin
bal
show
follow
least
hemosiderinladen
macrophag
blood
least
alveolar
surfac
progress
bloodier
return
serial
lavag
dah
manifest
dyspnea
nonproduct
cough
hemoptysi
hypoxemia
without
fever
may
progress
radiograph
diffus
alveolar
interstiti
infiltr
predominantli
central
basilar
distribut
particularli
suggest
dah
howev
pattern
diffus
opac
may
seen
fig
although
propos
biolog
distinct
subtyp
ip
dah
epidemiolog
poor
outcom
similar
ip
whole
studi
specif
examin
dah
transplant
set
incid
rang
similar
rate
autolog
allogen
hct
median
onset
rang
day
hct
risk
factor
dah
includ
myeloabl
condit
tbi
increas
age
respiratori
failur
requir
mechan
ventil
occur
case
overal
mortal
rang
highdos
system
corticosteroid
support
care
may
includ
platelet
transfus
standard
procoagul
therapi
variabl
success
small
studi
routin
use
delay
pulmonari
toxic
syndrom
delay
pulmonari
toxic
syndrom
subtyp
ip
occur
autolog
hct
present
exert
dyspnea
nonproduct
cough
often
fever
reduc
diffus
capac
radiograph
find
bilater
groundglass
linearnodular
consolid
mix
opac
incid
receiv
prehct
condit
regimen
contain
carmustin
bcnu
cyclophosphamid
cisplatin
combin
median
time
onset
day
rang
day
treatment
corticosteroid
mgkgd
result
resolut
case
cryptogen
organ
pneumonia
cop
previous
call
bronchiol
obliteransorgan
pneumonia
idiopath
interstiti
pneumonia
occur
hct
cop
typic
manifest
subacut
ill
character
fever
dyspnea
nonproduct
cough
howev
time
pace
onset
cop
vari
sever
rang
mild
sever
respiratori
failur
median
onset
day
hct
risk
factor
includ
acut
chronic
gvhd
femal
donor
male
recipi
condit
combin
cyclophosphamid
tbi
radiograph
commonli
show
unilater
bilater
patchi
foci
consolid
groundglass
opac
subpleur
peribronchi
bandlik
pattern
fig
pulmonari
function
test
show
ventilatori
restrict
reduc
diffus
capac
without
obstruct
definit
diagnosi
cop
requir
surgic
lung
biopsi
howev
case
present
typic
clinic
featur
bronchoscopi
exclud
infecti
pneumonia
may
justifi
treatment
trial
histolog
sampl
character
patchi
prolifer
immatur
fibroblast
call
masson
bodi
matrix
loos
connect
tissu
involv
termin
airway
alveolar
duct
alveoli
without
bronchiolar
intralumin
polyp
cop
often
resolv
sever
month
corticosteroid
therapi
frequent
relaps
discontinu
steroid
one
studi
cop
case
treat
mgkgd
prednisolon
follow
hct
resolv
remain
stabl
progress
result
case
fatal
acut
fibrin
organ
pneumonia
afop
recent
recogn
rare
poorli
understood
complic
hct
afop
may
part
spectrum
nonspecif
dysregul
respons
lung
injuri
along
diffus
alveolar
damag
cop
afop
coexist
cop
mark
wors
prognosi
origin
seri
afop
case
describ
acut
subacut
respiratori
ill
bibasilar
reticular
nodular
infiltr
histolog
afop
character
patchi
aggreg
intraalveolar
fibrin
deposit
fibrin
ball
associ
organ
pneumonia
case
neutrophil
inflamm
alveolar
wall
clinic
cours
afop
follow
one
trajectori
fulmin
respiratori
failur
subacut
diseas
recoveri
treatment
corticosteroid
corticosteroid
mycophenol
mofetil
dual
therapi
may
effect
sever
case
pattern
pulmonari
toxic
caus
drug
use
prehct
condit
gvhd
list
tabl
drug
categor
establish
toxic
hct
drug
toxic
observ
outsid
hct
set
carmustin
bcnu
sometim
use
alon
combin
autolog
hct
associ
acuteonset
pneumon
incid
prior
mediastin
radiat
therapi
bcnu
dose
greater
mg
age
younger
year
risk
factor
develop
pneumon
autolog
hct
lymphoma
noncardiogen
pulmonari
edema
ard
report
associ
cyclosporin
bone
marrow
transplant
resolv
medic
discontinu
postul
idiosyncrat
reaction
sirolimu
use
acut
gvhd
prophylaxi
primari
immunosuppress
activ
chronic
gvhd
caus
rare
pulmonari
toxic
may
sever
fatal
predomin
histolog
pattern
organ
pneumonia
pulmonari
hemorrhag
diffus
alveolar
damag
minor
case
pulmonari
alveolar
proteinosi
mainstay
treatment
discontinu
drug
without
corticosteroid
mgkgd
typic
result
complet
resolut
symptom
within
month
chemotherapeut
immunosuppress
agent
use
hct
known
pulmonari
toxic
clinic
set
consid
evalu
lung
diseas
follow
hct
cyclophosphamid
use
combin
tbi
chemotherapi
agent
prepar
regimen
hct
associ
interstiti
pneumonia
fludarabin
purin
analogu
use
nonmyeloabl
condit
regimen
allogen
hct
infrequ
associ
pulmonari
toxic
form
interstiti
pneumon
less
commonli
acut
eosinophil
pneumonia
usual
day
last
dose
case
respond
system
corticosteroid
therapi
mgkgd
suggest
immunolog
mechan
pathogenesi
fludarabineassoci
pulmonari
toxic
recur
steroid
taper
improv
reinstitut
steroid
therapi
monoclon
antibodi
use
prophylaxi
treatment
acut
gvhd
infrequ
associ
pulmonari
toxic
rituximab
chimer
antibodi
result
ard
dah
develop
within
hour
administr
interstiti
pneumon
cop
develop
within
week
case
resolv
complet
discontinu
therapi
without
corticosteroid
case
seri
renal
transplant
recipi
report
dah
treatment
alemtuzumab
cytolyt
monoclon
antibodi
use
reducedintens
condit
regimen
decreas
incid
sever
acut
chronic
gvhd
reduc
graft
reject
pulmonari
alveolar
proteinosi
pap
termin
bronchiol
alveoli
accumul
pulmonari
surfact
amorph
period
acid
schiff
pa
posit
lipoprotein
consequ
macrophag
dysfunct
pap
present
cough
dyspnea
hypoxemia
diffus
alveolar
opac
central
mid
lower
lung
predomin
congenit
autoimmun
secondari
form
pap
congenit
autoimmun
type
aris
malform
granulocytemacrophag
colonystimul
factor
gmcsf
receptor
format
antigmcsf
autoantibodi
respect
secondari
pap
occur
rare
hct
possibl
macrophag
deplet
antigmcsf
alloantibodi
diagnosi
suggest
bronchoscopi
yield
opaqu
milki
bal
fluid
pasposit
materi
present
within
macrophag
exclus
infecti
pneumonia
howev
lung
biopsi
requir
definit
diagnosi
pap
hct
may
selflimit
also
progress
fatal
respiratori
failur
optim
treatment
rare
entiti
includ
role
gmcsf
therapi
unknown
done
set
whole
lung
lavag
consid
sever
case
restor
alveolar
ventil
repeat
lavag
consid
recurr
venou
thromboembol
vte
underrecogn
complic
hct
retrospect
studi
hct
recipi
incid
symptomat
vte
within
first
day
transplant
includ
incid
noncatheterassoci
lower
extrem
deep
venou
thrombosi
dvt
incid
pulmonari
embol
median
time
hct
admiss
develop
noncatheterassoci
lower
extrem
dvt
pulmonari
embol
day
respect
prior
vte
gvhd
risk
factor
develop
vte
hct
thrombocytopenia
partial
protect
develop
vte
safeti
efficaci
thromboprophylaxi
patient
hct
remain
uncertain
patient
thrombocytopenia
anticoagul
therapi
document
vte
accompani
platelet
transfus
maintain
platelet
count
l
greater
reduc
risk
bleed
complic
pulmonari
cytolyt
thrombu
pct
seen
exclus
allogen
hct
recipi
almost
alway
children
incid
pct
report
rang
median
onset
month
rang
month
transplant
clinic
manifest
includ
fever
cough
respiratori
distress
radiograph
find
rang
small
peripher
nodul
diffus
opac
diagnosi
requir
lung
biopsi
histolog
character
vascular
occlus
distal
pulmonari
vessel
entrap
leukocyt
endotheli
disrupt
infarct
adjac
tissu
singlecent
retrospect
studi
grade
ii
iv
acut
chronic
gvhd
independ
risk
factor
develop
pct
treatment
pct
consist
system
corticosteroid
prednison
mgkgd
pulmonari
symptom
resolv
typic
within
week
follow
steroid
taper
week
strong
associ
acut
chronic
gvhd
well
respons
corticosteroid
therapi
suggest
pct
manifest
alloreact
lung
injuri
prognosi
pct
favor
report
death
attribut
entiti
pulmonari
hypertens
occur
hct
secondari
varieti
caus
manag
treat
underli
problem
includ
vte
left
heart
failur
hypoxemiainduc
diseas
pulmonari
parenchyma
airway
pulmonari
arteri
hypertens
pah
rare
report
hct
best
describ
clinic
context
section
focus
pulmonari
venoocclus
diseas
pvod
syndrom
increas
vascular
resist
rare
caus
fatigu
dizzi
weak
dyspnea
hct
overlap
clinic
featur
pvod
easili
misdiagnos
pah
may
repres
spectrum
process
howev
import
distinguish
pah
therapeut
implic
discuss
later
true
incid
risk
factor
outcom
pvod
hct
unknown
given
lack
prospect
studi
nonspecif
earli
manifest
heterogen
clinic
phenotyp
report
mortal
close
year
diagnosi
pvod
hypothes
aris
hctrelat
vascular
endotheli
damag
character
pulmonari
interstiti
edema
capillari
congest
due
fibrou
occlus
postcapillari
venul
sometim
larger
vein
result
elev
capillari
pressur
pvod
may
accompani
radiograph
evid
pulmonari
edema
pleural
effus
elev
pulmonari
arteri
pressur
may
detect
echocardiogram
howev
cardiac
catheter
recommend
confirm
elev
pulmonari
vascular
resist
triad
increas
pulmonari
vascular
resist
normal
left
heart
fill
pressur
radiograph
edema
variabl
present
pvod
therefor
surgic
lung
biopsi
consid
import
prognost
referr
lung
transplant
mani
therapi
use
clinic
set
tri
pvod
develop
hct
supplement
oxygen
prescrib
patient
hypoxemia
although
case
report
describ
benefit
system
anticoagul
immunosuppress
especi
presenc
autoimmun
featur
role
therapi
contemporari
era
pulmonari
vasodil
therapi
unknown
case
trial
system
immunosuppress
may
reason
addit
potenti
therapi
includ
diuret
inotrop
pulmonari
vasodil
eg
calcium
channel
blocker
inhibitor
endothelin
receptor
antagonist
prostanoid
contrast
pah
histor
experi
pulmonari
vasodil
pvod
demonstr
mix
result
vasodil
may
caus
harm
even
death
patient
predominantli
postcapillari
vascular
constrict
alveolar
flood
may
result
increas
perfus
region
fix
high
postcapillari
resist
consult
pulmonari
hypertens
specialist
advis
give
vasodil
inotrop
popul
therapi
may
safe
initi
close
monitor
set
transfusionrel
acut
lung
injuri
trali
defin
noncardiogen
pulmonari
edema
respiratori
failur
occur
within
hour
blood
compon
transfus
trali
like
underrecogn
highli
transfus
hct
popul
trali
caus
activ
pulmonarysequest
neutrophil
respons
passiv
transfus
antibodi
activ
substanc
trali
may
mild
result
mechan
ventil
death
treatment
support
care
broad
spectrum
noninfecti
pulmonari
syndrom
contribut
morbid
mortal
hct
awar
syndrom
describ
articl
practition
diagnos
import
caus
pulmonari
dysfunct
institut
appropri
therapi
research
need
identifi
individu
risk
syndrom
better
elucid
biolog
effort
find
effect
therapi
